111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy
111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy
复制标题
DOI：
10.1016/s0022-5347(01)63239-7
复制
发表时间：
1998-06-01
影响因子：
6.6
通讯作者：
Maguire, RT
中科院分区：
文献类型：
--
作者：
Kahn, D;Williams, RD;Maguire, RT
目的：标准诊断方法仅限于检测前列腺癌患者的远处转移，其中根治性前列腺切除术后疾病的唯一证据是可检测的前列腺特异性抗原（PSA）水平。我们评估的作用，免疫闪烁与放射性标记的单克隆抗体，（111）铟（In-111）-caporumab pendetide，区分局部和远处复发，在此patient population.Materials和方法：我们招募了183名男子谁经历了根治性前列腺切除术，其中PSA后来增加。输注单剂量In-111-caprolumab pendetide后，采集了两次伽马相机图像。结果：免疫闪烁成像显示181名患者中的108名（60%）的扫描结果可解释。抗体最常定位于前列腺窝（34%的病例）、腹部淋巴结（23%）和盆腔淋巴结（22%）。在181名男性中，42%的扫描定位在前列腺窝外的抗体。一半的阳性定位在窝被证实活检。结论：这些研究结果表明，免疫闪烁与In-111-caporumab pendetide可以帮助确定疾病的程度，在前列腺切除术后PSA增加的患者。
Purpose: Standard diagnostic methods are limited for detecting distant metastases in patients with prostate cancer in whom the only evidence of disease after radical prostatectomy is a detectable prostate specific antigen (PSA) level. We evaluated the role of immunoscintigraphy with the radiolabeled monoclonal antibody, (111)indium (In-111)-capromab pendetide, to differentiate between local and distant recurrence in this patient population.Materials and Methods: We enrolled 183 men who had undergone radical prostatectomy in whom PSA later increased. Gamma camera images were acquired twice after infusion of a single dose of In-111-capromab pendetide.Results: Immunoscintigraphy revealed disease in 108 of 181 patients (60%) with interpretable scans. The antibody was localized most frequently to the prostatic fossa (34% of the cases), abdominal lymph nodes (23%) and pelvic lymph nodes (22%). Of the 181 men the scan localized the antibody outside the prostatic fossa in 42%. Half of the positive localizations in the fossa were confirmed by biopsy.Conclusions: These findings suggest that immunoscintigraphy with In-111-capromab pendetide can assist in determining the extent of disease in patients who have increasing PSA after prostatectomy.